Search

Bio-Techne Corp

Затворен

СекторЗдравеопазване

71.93 0.39

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

71.51

Максимум

71.83

Ключови измерители

By Trading Economics

Приходи

13M

51M

Продажби

16M

311M

P/E

Средно за сектора

103.826

62.58

EPS

0.53

Дивидентна доходност

0.44

Марж на печалбата

16.392

Служители

3,100

EBITDA

21M

99M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

-6.34% downside

Дивиденти

By Acuity

Дивидентна доходност

Средно за сектора

0.44%

2.19%

Следващи печалби

5.08.2026 г.

Следваща дата на дивидент

28.08.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

2.6B

11B

Предишно отваряне

71.54

Предишно затваряне

71.93

Настроения в новините

By Acuity

65%

35%

296 / 340 Класиране в Healthcare

Bio-Techne Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.07.2026 г., 18:01 ч. UTC

Bio-Techne Corp shares are lower today, with no specific news identified. Broader market pressures include rising yields and inflation concerns linked to oil prices.

Сравнение с други в отрасъла

Ценова промяна

Bio-Techne Corp Прогноза

Ценова цел

By TipRanks

-6.34% надолу

12-месечна прогноза

Среден 67.09 USD  -6.34%

Висок 73 USD

Нисък 50 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Bio-Techne Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

14 ratings

1

Купи

13

Задържане

0

Продай

Настроение

By Acuity

296 / 340 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat